Pyros Patent-Cliff Exposure & CMS Drug Spending Portfolio

Pyros (US): 1 reconciled FDA prescription therapies, $1.7M 2024 CMS Part D & Medicaid spend, and $3,235 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2043-01-01
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.7M
California HCAI SB 17 FilingsSpecialty launch notice ($3,235 intro WAC)